Novavax, Inc. (NVAX)
Current
- (-)
After Hours
Rating Performance
Rating Return
+0.0% vs
Rating Accuracy
0% (0 of 0*)
Rating Return
+0.0% vs
Rating Accuracy
0% (0 of 0*)
Rating Return
-69.73% vs
Rating Accuracy
0% (0 of 1*)
Rating Return
-90.33% vs
Rating Accuracy
16.67% (1 of 6*)
FV Performance
FV Accuracy
0 Hits (0% Hit Rate)
FV Avg. Distance
+270.8%
FV Accuracy
0 Hits (0% Hit Rate)
FV Avg. Distance
+263.18%
FV Accuracy
0 Hits (0% Hit Rate)
FV Avg. Distance
+239.01%
FV Accuracy
2 Hits (4.17% Hit Rate)
FV Avg. Distance
+117.4%
*There is a current rating on the stock that is included in these numbers based on its performance so far
About
CEO
Stanley C. Erck
Employees
165
Industry
Infectious Disease Biopharmaceuticals
Sector
Healthcare
Headquarters
Gaithersburg
Exchange
NASDAQ
Website
http://www.novavax.comSummary Stats
Market Cap
4.21B
Revenue
1.4B
Net Income
-1.32B
EPS
-$17.26
Price-to-Earnings
-3.12
Price-to-Book
64.38
Debt-to-Equity
42.4
News
Analyst Ratings
Price targets projected by 5 analysts
High
$223.00
Average
$186.20
Low
$75.00
Ratings calculated by 6 analysts
Buy
4
Hold
1
Sell
1
Last Dividend
Amount
-
Dividend Date
-
Frequency
-
Dividend Yield
Earnings
Most Recent Earnings
Last Earnings for Q1 2022
Missed by -$0.13
$2.56 -4.8%
2.69
-3.05
Up 183%
Actual vs Estimates
XX
xxx
Upcoming Estimates Unavailable
-
-
-
--